Epigenomcs AG acts as a holding company and is dedicated to managing its own assets, acquiring, holding and disposing of investments in companies in Germany and abroad, particularly in the field of minimally invasive blood tests for cancer detection, as well as investing in other assets.
Latest News
Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
Preliminary announcement | 29 July 2024 15:39 Epigenomics AG / Preliminary announcement on the disclosure of financial statements Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] 29.07.2024 / 15:39 CET/CEST Preliminary announcement of the publication of financial reports according to […]
Epigenomics AG: Preliminary half-year results as at June 30, 2024
Ad-hoc | 22 July 2024 17:49 Epigenomics AG / Schlagwort(e): Halbjahresergebnis Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 22.07.2024 / 17:49 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch EQS News – ein Service der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber […]
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Gesamtstimmrechte | 10 April 2024 11:33 Epigenomics AG / Total Voting Rights Announcement Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10.04.2024 / 11:33 CET/CEST Total Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG. The issuer […]
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
EQS-News: Epigenomics AG / Key word(s): PersonnelEpigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 30.04.2024 / 15:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 Berlin (Germany), April 30, 2024 – Jens Ravens, Executive […]
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Gesamtstimmrechte | 10 April 2024 11:33 Epigenomics AG / Total Voting Rights Announcement Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10.04.2024 / 11:33 CET/CEST Total Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG. The issuer […]
Epigenomics AG publishes financial results for fiscal year 2023
EQS-News: Epigenomics AG / Key word(s): Annual Results/Annual ReportEpigenomics AG publishes financial results for fiscal year 2023 14.03.2024 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG publishes financial results for fiscal year 2023 Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial […]
